Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2023 Earnings Call Transcript

Myles Minter: Thanks.

Operator: Thank you. We have reached the end of our question-and-answer session. I’d like to turn the floor back over to management for any further or closing comments.

Herriot Tabuteau: Well, thank you again for taking the time out of your busy schedule for joining us for today’s update. We are excited to continue building our industry-leading CNS franchise in the back half of 2023. We anticipate a milestone billed next few months with potential clinical trial readouts, new trial initiations and new submissions. We are committed to ensuring continued success for the launch of Auvelity and commercial growth for Sunosi and our fast on our way to achieving our goal of potentially having at least five marketed products by 2025. We look forward to updating you on our progress and milestones throughout the rest of the year. Have a great rest of your day.

Operator: Thank you. That does conclude today’s teleconference and webcast. You may disconnect your line at this time, and have a wonderful day. We thank you for your participation today.